HIV Treatment and Prevention Agents, Hospitals and Vaccines

Pharmacists Have a Crucial Role Helping Patients With ATTR-CM Navigate Treatment With Tafamidis

Pharmacy Times

JULY 1, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Specialty Pharmacies Compounding Pharmacies Hospitals

Impact of Patient Access to Care on Rates of Febrile Neutropenia Post Inpatient Administration of a Colony-Stimulating Factor

Pharmacy Times

JUNE 16, 2025

Although the use of colony-stimulating factors (CSFs) is well-established in mitigating severe FN, existing literature suggests there is only an approximate 3% difference in FN rates between various CSF agents.

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Chemotherapy Compounding Pharmacies Immunization

FDA Approves Meloxicam Injection For Moderate-to-Severe Pain in Adults

Pharmacy Times

JUNE 10, 2025

The convenience of once-daily dosing and a rapid IV bolus administration may offer workflow efficiencies in hospital or surgical settings, where minimizing polypharmacy and streamlining medication administration are important goals.

FDA

FDA HIV Treatment and Prevention Agents Compounding Pharmacies Hospitals

ADA 2025: Advances in Type 2 Diabetes Management With Tirzepatide

Pharmacy Times

JUNE 23, 2025

The presentation emphasized early intervention and personalized treatment plans in managing type 2 diabetes, shifting from "treating to failure" to "treating to target." It is not indicated for type 1 diabetes and carries a boxed warning for thyroid C-cell tumors, with unknown risk in humans.

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Compounding Pharmacies Immunization FDA

Infliximab Biosimilar Initiation Has Increased in Pediatric IBD, Study Finds

Pharmacy Times

JULY 8, 2025

Further research is needed on the clinical impact, treatment longevity, and cost implications of biosimilar use in pediatric IBD. The study found no significant differences in biosimilar use by age, race, or ethnicity, but regional variations existed. SHOW MORE The study found biosimilar initiation rose to nearly 42% from 2016 to 2023.

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Compounding Pharmacies Immunization Hospitals

Analysis shows Yeztugo approval a ‘momentous step’ for HIV prevention

Pharmaceutical Technology

JULY 2, 2025

How will RFK Jr’s American dream for vaccines play out? Gilead’s recently approved drug for HIV prevention, Yeztugo (lenacapavir), has the potential to transform the pre-exposure prophylaxis (PrEP) sector in the US, according to market analysts. Reports LOA and PTSR Model - GS-1720 in Human Immunodeficiency Virus (HIV).

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Packaging FDA Communication

Protecting Older Adults from Severe RSV: Key Challenges and the Importance of Prevention

Pharmacy Times

JULY 3, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Compounding Pharmacies Vaccines Hospitals

Gilead hit with FDA clinical hold for batch of HIV trials

Pharmaceutical Technology

JUNE 11, 2025

The US Food and Drug Administration (FDA) has placed a clinical hold on several of Gilead’s trials evaluating two HIV treatment candidates, though the rest of the drugmaker’s diverse pipeline remains unaffected. Gilead is considered the leading big pharma in HIV treatments. Shares in Nasdaq-listed Gilead opened 0.3%

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents FDA Communication Hospitals

Rethinking the fight against TB: insights from ESCMID Global

Hospital Pharmacy Europe

JUNE 19, 2025

Despite longstanding knowledge that TB is both preventable and curable, progress has stalled. Vaccines, diagnostics and the latency problem An important contributor to this inertia is because the medical community is ‘still using old tools’ in the fight against TB, according to Professor Thwaites. million deaths in 2023.

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Vaccines Hospitals

Oral COVID Agents

Pharmacy Friday Pearls

MARCH 4, 2022

18 years Administration Oral Oral Oral PK/PD MOA: Nirmatrelvir – inhibitor of the SARS-CoV-2 main protease Prevents viral replicationRitonavir is a CYP3A inhibitor included to increase nirmatrelvir plasma levelsRitonavir alone has NO activity against SARS-CoV-2 Time to peak: Nirmatrelvir: 3 hrs & Ritonavir: 3.98 Introduction.

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Hospitals Packaging Immunization

Ivermectin: A therapeutic approach to reduce high-risk cases of COVID

Druggist

SEPTEMBER 2, 2021

With an ongoing vaccination program globally, experts hope that a large world population will soon get a vaccine that protects against corona. Additionally, this drug is also known as anti-parasite successful against all viruses like HIV, Dengue, Influenza , and Zika virus. How effective is Ivermectin for Corona?

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Adverse Reactions Hospitals FDA

Pneumonia symptoms: What are the early signs of pneumonia?

The Checkup by Singlecare

FEBRUARY 6, 2023

Pneumonia is often mild to moderate, requiring only outpatient treatment. Rarely can it be severe enough to require intensive care in a hospital? Risk factors of pneumonia are age older than 65, chronic obstructive pulmonary disorder ( COPD ), HIV infection , weakened immune system and smoking. Treatment depends on the cause.

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Vaccines Hospitals Immunization

Pharmacy Technician Pulse

Pharmacists Have a Crucial Role Helping Patients With ATTR-CM Navigate Treatment With Tafamidis

Impact of Patient Access to Care on Rates of Febrile Neutropenia Post Inpatient Administration of a Colony-Stimulating Factor

Trending Sources

FDA Approves Meloxicam Injection For Moderate-to-Severe Pain in Adults

ADA 2025: Advances in Type 2 Diabetes Management With Tirzepatide

Infliximab Biosimilar Initiation Has Increased in Pediatric IBD, Study Finds

Analysis shows Yeztugo approval a ‘momentous step’ for HIV prevention

Protecting Older Adults from Severe RSV: Key Challenges and the Importance of Prevention

Gilead hit with FDA clinical hold for batch of HIV trials

Rethinking the fight against TB: insights from ESCMID Global

Oral COVID Agents

Ivermectin: A therapeutic approach to reduce high-risk cases of COVID

Pneumonia symptoms: What are the early signs of pneumonia?

Stay Connected